Simparica Trio 3mg for Dogs - Pack of 6 Chewable Tablets

Description

3mg Simparica Trio Chewable Tablets for Dogs - Pack of 6

Simparica Trio Chewable Tablets for Dogs 3mg are indicated for the treatment of dogs (1.25kg-2.5kg) with, or at risk from, mixed external and internal parasitic infestations. Simparica Trio Tablets are exclusively indicated when use against ticks or fleas, and gastrointestinal nematodes are indicated at the same time.

Simparica Trio also provides concurrent efficacy for the prevention of heartworm disease and angiostrongylosis.

Each Simparica Trio Tablet Contains: Sarolaner 24mg, Moxidectin 0.48mg, Pyrantel (as embonate) 100mg

Legal Category:

Simparica Trio is a POM-V (Veterinary Pet Prescription Required)

Ectoparasites - Simparica Trio can be used for the treatment of tick infestations. Simparica Trio has immediate and persistent tick killing activity for 5 weeks against Ixodes hexagonus, Ixodes ricinus and Rhipicephalus sanguineus and for 4 weeks against Dermacentor reticulatus;

Simparica Trio can be used for the treatment of flea infestations (Ctenocephalides felis and Ctenocephalides canis). Simparica Trio has immediate and persistent flea killing activity against new infestations for 5 weeks;

Simparica Trio can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD). Gastrointestinal nematodes •For the treatment of gastrointestinal roundworm and hookworm infections: •Toxocara canis immature adults (L5) and adults; •Ancylostoma caninum L4 larvae, immature adults (L5) and adults; •Toxascaris leonina adults; •Uncinaria stenocephala adults. Other nematodes •For the prevention of heartworm disease (Dirofilaria immitis); •For the prevention of angiostrongylosis by reducing the level of infection with immature adult (L5) stages of Angiostrongylus vasorum.

Dosage and administration
For oral use. Simparica Trio should be administered at a dose of 1.2-2.4 mg/kg of sarolaner, 0.024-0.048 mg/kg moxidectin and 5-10 mg/kg of pyrantel in accordance with the following table.